|Day Low/High||160.06 / 162.48|
|52 Wk Low/High||109.16 / 164.14|
It is all about perception, and here are strong names to pick up on market weakness.
These stocks offer not only terrific histories of dividend increases, but are also trading at reasonable valuations.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Bulls see a $158 price target, but JNJ needs a rally to $135.28 for a breakout.
These funds from the Shark Tank star's O'Shares series focus on small-cap dividend names, internet giants and large-cap dividend U.S. dividend stocks.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer is bullish on Johnson & Johnson shares.
How can this be? Let's take a look at the camps so we can figure it out.
When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.
My Netflix short was a big winner yesterday, but I am also long Amazon and Google, which were hit with pretty strong collateral damage.
This quarter Netflix is not going to be the star of earnings season.
The major U.S. indices rose on Friday, closing out the week on a two-day winning streak.
We aren't done moving higher even with the president ready to strike at a moment's notice against any of our allies.
Happy Friday the 13th! These are the stories moving the market ahead of today's opening bell.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks from the floor of the New York Stock Exchange
The only way the market is "dangerously elevated" is if you believe that 2019 is going to be a horrendous year.
These 'recession-resistant' names have proven they can thrive in a variety of economic conditions and through changing technologies and sentiments.
Johnson & Johnson is among the companies that Jim Cramer has put on his new GLOOM index.
Taking the measure of what's keeping the markets in the dumps.
The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Tech and retail gains aren't enough to lead markets to new highs.
JNJ is one of the best of breed of the pharmaceuticals sector.
Johnson & Johnson is a premiere company, but the trick is knowing when to buy it.
Shares of the healthcare giant pick up a quant rating upgrade as the charts suggest gains ahead.
The potential of these setups on the weekly chart is rather good.
What's really surprising is the emergence of so many household names on the list.
The Nasdaq U.S. Broad Dividend Achievers Index is a good place to start.